

Protein Classifier for Thyroid Nodules Learned from Rapidly Acquired Proteotypes

Yaoting Sun^{1,2#}, Sathiyamoorthy Selvarajan^{3#}, Zelin Zang^{4#}, Wei Liu^{1,2,5#}, Yi Zhu^{1,2#}, Hao Zhang^{6#}, Hao Chen^{1,2}, Xue Cai^{1,2}, Huanhuan Gao^{1,2}, Zhicheng Wu^{1,2}, Lirong Chen⁷, Xiaodong Teng⁸, Yongfu Zhao⁹, Sangeeta Mantoo³, Tony Kiat-Hon Lim³, Bhuvanewari Hariraman¹⁰, Serene Yeow¹¹, Syed Muhammad Fahmy bin Syed Abdillah³, Sze Sing Lee¹¹, Guan Ruan^{1,2}, Qiushi Zhang^{1,2}, Tiansheng Zhu^{1,2}, Weibin Wang¹², Guangzhi Wang⁹, Junhong Xiao⁹, Yi He¹³, Zhihong Wang⁶, Wei Sun⁶, Yuan Qin⁶, Qi Xiao^{1,2}, Xu Zheng¹⁴, Linyan Wang¹⁵, Xi Zheng¹⁶, Kailun Xu¹⁶, Yingkuan Shao¹⁶, Kexin Liu⁵, Shu Zheng¹⁶, Ruedi Aebersold^{17,18}, Stan Z. Li^{4*}, Oi Lian Kon^{11*}, N. Gopalakrishna Iyer^{10,11*}, Tiannan Guo^{1,2,19*}

¹Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China;

²Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China;

³Department of Pathology, Singapore General Hospital, Republic of Singapore;

⁴School of Engineer, Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China;

⁵Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, No.9 West Section Lvshun South Road, Dalian 116044, Liaoning Province, China;

⁶Department of Thyroid Surgery, the First Hospital of China Medical University, No.155 Nanjing Bei Street, Shenyang 110001, Liaoning Province, China;

⁷Department of Pathology, The Second Affiliated Hospital of College of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China;

⁸Department of Pathology, the First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310024, Zhejiang Province, China;

⁹Department of General Surgery, The Second Hospital of Dalian Medical University, 467 Zhongshan Road, Dalian 116027, Liaoning Province, China;

¹⁰Division of Surgical Oncology, National Cancer Centre Singapore, Republic of Singapore;

¹¹Division of Medical Sciences, National Cancer Centre Singapore, Republic of Singapore;

¹²Department of Surgical Oncology, the First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310024, Zhejiang Province, China;

¹³Department of Urology, The Second Hospital of Dalian Medical University, 467 Zhongshan Road, Dalian 116027, Liaoning Province, China;

¹⁴Liaoning Laboratory of Cancer Genetics and Epigenetics and Department of Cell Biology, College of Basic Medical Sciences, Dalian Medical University, No.9 West Section Lvshun South Road, Dalian 116044, Liaoning Province, China;

¹⁵Department of Ophthalmology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China;

¹⁶Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China;

¹⁷Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

44 ¹⁸Faculty of Science, University of Zurich, 8093 Zurich, Switzerland

45 ¹⁹Lead contact

46 #Co-first authors;

47 *Correspondence: Stan.ZQ.Li@westlake.edu.cn (S.Z.L.); kairos712@singnet.com.sg (O.L.K.);

48 gopaliyer@singhealth.com.sg (N.G.I.); guotiannan@westlake.edu.cn (T.G.)

49 SUMMARY

50 Up to 30% of thyroid nodules cannot be accurately classified as benign or malignant by
51 cytopathology. Diagnostic accuracy can be improved by nucleic acid-based testing, yet
52 a sizeable number of diagnostic thyroidectomies remains unavoidable. In order to
53 develop a protein classifier for thyroid nodules, we analyzed the quantitative proteomes
54 of 1,725 retrospective thyroid tissue samples from 578 patients using pressure-cycling
55 technology and data-independent acquisition mass spectrometry. With artificial neural
56 networks, a classifier of 14 proteins achieved over 93% accuracy in classifying
57 malignant thyroid nodules. This classifier was validated in retrospective samples of 271
58 patients (91% accuracy), and prospective samples of 62 patients (88% accuracy) from
59 four independent centers. These rapidly acquired proteotypes and artificial neural
60 networks supported the establishment of an effective protein classifier for classifying
61 thyroid nodules.

62 **Keywords:** Thyroid nodule; Proteomics; Data-independent acquisition; Artificial neural
63 networks; Pressure cycling technology; Mass spectrometry

65 INTRODUCTION

66 Advances in imaging technology and liberal screening practices have identified
67 thyroid nodules in up to 50% of the general population, but only a small minority (7-15%)
68 eventually prove to be malignant by histology, and even fewer among these are
69 clinically relevant (Burman and Wartofsky, 2015; Jameson, 2012). Beyond clinical
70 assessment and ultrasonography, fine needle aspiration (FNA) followed by
71 cytopathology is considered the most reliable pre-surgical technique for differentiating
72 benign from malignant thyroid tumors (Burman and Wartofsky, 2015; Faquin et al.,
73 2011). Yet up to one-third of thyroid nodules are deemed indeterminate by FNA-
74 cytopathology (Alexander et al., 2012), and surgery remains the only option for accurate
75 diagnosis. However, the majority of thyroid surgeries are diagnostic procedures
76 undertaken to exclude thyroid cancer, of which no more than 25% accomplish any
77 therapeutic purpose (Ahn et al., 2014). Patients whose thyroid glands are removed in
78 part or entirely often require daily and lifelong thyroxine-replacement therapy and
79 medical monitoring. Given that only 10% of resected glands prove to be malignant, the
80 current clinical approach results in substantial over-treatment with unwarranted surgical
81 risks for patients who could otherwise be treated conservatively (Vaccarella et al.,
82 2016).

83 Molecular tests adjunctive to FNA-cytopathology have focused on RNA expression
84 or DNA mutational profiling of aspirates obtained prior to surgery, using small quantities

85 of RNA or DNA that can be amplified (Eszlinger et al., 2017). The Afirma® gene
86 expression classifier (GEC) determines RNA abundances of 142 genes with high
87 sensitivity and negative predictive value (NPV) of up to 92% and 93%, respectively.
88 However, positive predictive value (PPV) and specificity for diagnosing malignancy are
89 only 47% and 52%, respectively (Alexander et al., 2012). The latest version of Afirma®
90 called GSC has achieved a sensitivity of 91%, but the specificity was only 68% (Patel et
91 al., 2018). The ThyroSeq (v3.0) test combines mutation and expression profiling for
92 better accuracy (Nikiforova et al., 2013), but has other limitations i.e. the need for fresh
93 tissue samples with un-degraded RNA, and test data processing by central 'black box'
94 analysis. A recent review of the GEC test showed sensitivities of 83-100% but low
95 overall specificity, ranging from 10 to 52% across multiple centers. This may reflect
96 variability in sample composition, issues with tissue quality and the fragility of nuclei
97 acid-based testing in general (Wang and Sosa, 2018). While nucleic acid-based
98 approaches continue to be refined, for example with successive iterations of ThyroSeq
99 panels, there is evident scope for alternative approaches to address this diagnostic
100 dilemma.

101

102 Until recently, proteomics-based analyses were limited to large tissue quantities and
103 fresh/snap frozen samples. Proteotyping hundreds of biopsy-level tissue samples from
104 clinical cohorts remains unfeasible with conventional methods. We developed a
105 pressure cycling technology (PCT) protocol for proteomic analysis of tissue biopsy
106 samples (Guo et al., 2015) which can be performed on minimal amounts (0.2–1 mg) of
107 fresh-frozen tissue samples (Shao et al., 2016; Shao et al., 2015). The method was
108 recently extended to generate high quality proteome data from formalin-fixed, paraffin-
109 embedded (FFPE) tissue samples (Zhu et al., 2019), and in this study on fine-needle
110 thyroid gland aspirates. Coupled with Sequential Window Acquisition of all Theoretical
111 fragment ions (SWATH) mass spectrometry (MS), a data-independent acquisition (DIA)-
112 MS method (Gillet et al., 2012), this technique now permits practical proteomic analysis
113 of biopsy size FFPE tissue samples at high sample throughput. In this study we apply
114 this technology to analyze a large number of tissue samples and show that the high
115 quality proteotype data generated a robust panel of protein markers which differentiates
116 benign from malignant thyroid disease with high 'rule in' and 'rule out' accuracy.

117

118 **RESULTS**

119 **Study design and clinical characteristics**

120 We applied PCT-DIA on a total of 931 nodules from 911 patients using tissue cores
121 (1 mm diameter with 0.5-1 mm thickness) punched out from regions of interest marked
122 on FFPE tissue blocks, or from fine-needle aspiration (FNA) biopsies. The samples
123 comprise (i) a discovery set from Singapore General Hospital (n = 579 nodules) where
124 histopathological diagnoses were confirmed on central review by a board-certified
125 pathologist; and (ii) independent test sets from four hospitals in China consisting of
126 retrospective test sets of FFPE samples (n = 288 nodules) and prospective test set of
127 FNA biopsies (n = 64 nodules) (Figure 1A). The discovery set comprised FFPE samples
128 from 40 normal thyroid tissues (N), 203 multinodular goiters (MNG), 137 follicular

129 adenomas (FA), 75 follicular carcinomas (FTC) and 124 papillary carcinomas (PTC)
130 (Table 1; Table S1). For subsequent analyses, these were divided into benign
131 (comprising N, MNG and FA) and malignant (comprising FTC and PTC) thyroid nodules.
132 For each nodule in the discovery set, three punches were obtained from the region of
133 interest as biological replicates. In total, we analyzed 1,725 samples randomly
134 distributed into 121 batches to minimize batch effects (Figure 1B) using 45 min DIA-MS,
135 and an additional 56 randomly selected samples as technical replicates. These
136 technical replicates distributed randomly in the first 84 batches for the training sample
137 set. Although higher proteomic depth could be obtained with a longer LC gradient, we
138 adopted a reasonably fast analysis time to minimize batch effects without substantial
139 compromise of proteome depth (Sun, 2020), thus facilitating effective downstream
140 machine learning to establish a robust classifier.
141

142 **Global proteomic profiling of thyroid nodules**

143 To analyze the DIA data, we built a specific thyroid-tissue spectral library from FFPE
144 tissues containing 52 DDA files (Table S2) using a 120-min liquid chromatography (LC)
145 gradient on a Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer. Relatively
146 long gradient was adopted for DDA analysis to maximize the isolation of peptide
147 precursors. We constructed a spectral library containing 33,802 peptides from 5,190
148 protein groups using our previously established computational pipeline (Zhu, 2020). The
149 number of proteins in this library is relatively smaller than that of other tissue types
150 analyzed using a similar workflow (Guo et al., 2015; Shao et al., 2019; Zhu, 2020; Zhu
151 et al., 2019) or other proteomic protocols (Jiang et al., 2019; Sinha et al., 2019; Zhang
152 et al., 2016) as thyroid tissue contains a high abundance protein, thyroglobulin, which
153 weakens the signal for the rest of the proteome (M et al., 2018). Using OpenSWATH
154 (v2.0) and our thyroid library, we analyzed 1,781 DIA maps (1,725 FFPE cores and 56
155 technical replicates). We identified and quantified 30,915 peptides from 3,708 high-
156 confidence proteotypic proteins (Table S3). Details on quality control and reproducibility
157 (Figure S1) are detailed in the respective supplementary sections.

158 From these, we computed the average intensities of 2,617 proteotypic proteins
159 which were quantified with high confidence for each thyroid nodule, as visualized in a
160 tissue-type supervised heatmap (Figure 2A). Malignant tissue samples expressed
161 higher number of proteins than benign samples, indicating more diverse proteome of
162 tumor cells. To check whether the thus acquired proteotypes classifies different tissue
163 types, we applied uniform manifold approximation and projection (UMAP) algorithm to
164 visualize the 579 proteotypes from five tissue types (Figure 2B). The plot shows that
165 PTC samples are well isolated from the rest, indicating PTC samples are vastly different
166 in terms of proteome expression. We then grouped N, MNG and FA as benign group,
167 while FTC and PTC as the malignant group (Figure 2C). The UMAP visualization shows
168 that malignant samples are well resolved from benign samples with some overlap. We
169 further narrowed our focus to the N and MNG groups and found that their proteotypes
170 share high degree of similarity (Figure 2D). Not surprisingly, FA exhibited significant
171 overlap with both benign and malignant subsets, particularly between FA and FTC
172 (Figure 2E), corroborating biological overlap between the two pathologies, while there
173 were sufficient features that could distinguish FTC from PTC (Figure 2F). FA and FTC

174 could not be separated neither (Figure 2E). Pair-wise comparison of each two groups
175 are shown in Figure S2. The above analyses show that the proteotype maps thus
176 measured reasonably reflected the clinical phenotype of these samples.

177

178 **Feature selection and classifier development**

179 To derive a protein-based signature to differentiate benign from malignant thyroid
180 tumors, we developed a customized feature selection process combined with artificial
181 neural network algorithms based on the discovery dataset of 500 samples (Figure 3A).
182 The rest 79 samples serve as internal validation set. Here we limited the number of
183 selected features to no more than 20 so that they may be practically measured by
184 targeted proteomics or antibodies in clinic. We paid special attention to maximize the
185 specificity while keeping the sensitivity above 90% since the major problem of thyroid
186 nodule evaluation is over-diagnosis. Briefly, protein features selected by a genetic
187 algorithm (Mitchell, 1998) combined with 5-fold cross validation led us to identify a
188 classifier-panel of 14 proteins (Table 2) to separate benign and malignant nodules.
189 Individual protein expression levels are shown in Figure 4. Ten of these proteins have
190 been previously reported in thyroid cancers, including annexin A1 (Ciregia et al., 2016),
191 galectin-3 (Bartolazzi et al., 2018), SH3 domain-binding glutamic acid-rich-like protein 3
192 (Martínez-Aguilar et al., 2016), alpha 2-HS glycoprotein (Farrokhi Yekta et al., 2018),
193 myosin heavy chain 9 (Wang et al., 2017), phosphatidylethanolamine-binding protein 1
194 (Kim et al., 2010), clusterin (Kashat et al., 2010), LDL receptor related protein 2 (He et
195 al., 2020), calreticulin (Schürch et al., 2019) and moesin (Smith et al., 2019). In addition,
196 this list also includes two proteins involved thyroid functions, including tubulin folding
197 cofactor A (Figliozzi et al., 2017) and histone cluster 1 H1 family member c (Brix et al.,
198 1998). No previous association with thyroid disease has been reported for the remaining
199 two (Thy-1 cell surface antigen and sialic acid acetyltransferase).

200 We next compared seven different machine learning models for classification using
201 these 14 selected proteins. Receiver operating characteristics (ROC) plots showed the
202 model based on artificial neural networks described here achieved the highest area
203 under the curve (AUC) value of 0.95 and accuracy of 0.91 (Figure 3B). Using the 14
204 protein features in our established neural network model, each specimen was re-
205 classified into benign or malignant in the 500 samples in the discovery cohort. The
206 model comprised a 'feature extraction sub-model' which extracts and maps features
207 from protein data into a feature vector in latent space, and a 'classification sub-model'
208 which assigns a score (from 0 to 1) to the feature vector indicating the likelihood of
209 malignancy for each sample. The 'feature extraction sub-model' was trained using
210 contrastive loss function, while cross-entropy loss function was used to train the
211 classification sub-model. Details of the neural network model are described in
212 Supplementary Methods. We validated this model using the 79 internal validation
213 samples (Table S4; Figure S3A-S3B). ROC plot showed that our model achieved an
214 AUC value of 0.96 for the training dataset (n=500) used to derive this algorithm and
215 0.96 for the cross-validation dataset (n=79) (Figure 3C). t-SNE plot of the feature latent
216 space showed remarkable separation between malignant and benign tissue using the
217 14-protein panel.

218

219 **Performance of the protein classifier**

220 In order to validate this 14-protein model in an independent patient cohort, we first
221 analyzed 288 pathologist-reviewed FFPE tissues (n = 271 patients) from three high-
222 volume hospitals, comprising 144 benign and 144 malignant tissue samples. To ensure
223 rigorous validation, the diagnoses were blinded during data acquisition and analyses.
224 Each sample was analyzed using the PCT-DIA workflow in technical duplicates.
225 Analysis of the resulting 576 DIA maps identified 3,527 high-confidence proteotypic
226 proteins (Table S3). Individual ROC plots for samples from each of the three hospitals
227 using the 14-protein model showed AUC of >0.91 for the retrospective FFPE samples
228 (Figure 3D). Both scatter and t-SNE plots demonstrated distinct separation between
229 benign and malignant thyroid tissues (Figure 3D; Table S4), although there were
230 variations between individual sites (Figure S3C). The overall sensitivity and specificity
231 were 90% and 91%, respectively, with negative- (NPV) and positive-predictive values
232 (PPV) of 90% and 91%, respectively. Further details are provided in Table 3.

233 Given that the eventual objectives were to apply this analysis to pre-surgical FNA
234 biopsies, we extended validation to a separate prospective cohort of 64 FNA samples
235 (n=62 patients) obtained from a fourth independent clinical center. Even from these
236 small amounts of FNA biopsy tissues, we were able to generate a high-quality protein
237 matrix containing 3,310 proteotypic proteins using PCT-DIA technology (Table S3). The
238 model achieved an AUC value of 0.89 (Figure 3E) and correctly identified 56 of 64
239 samples with sensitivity, specificity, PPV and NPV of 87%, 89%, 95% and 73%,
240 respectively (Table 3). The predictive accuracy for all subtypes exceeded 91% except
241 FA (89%) and FTC (83%) (Figure 3F), likely due to similarity of histology (and potential
242 biological overlap) between these two pathologies.

244 **Biological insights on thyroid tumor subtypes**

245 We next asked whether the proteomic data could be used to reveal biological
246 insights of specific subtypes of thyroid neoplasms. In recent years, differentiated thyroid
247 cancers have been further sub-classified based on specific morphological features or
248 their expected clinical course. Hürthle cell adenomas and carcinomas are deemed as
249 distinct entities, with the latter demonstrating a higher propensity for metastasis (Ganly
250 et al., 2018; Gopal et al., 2018). The proteomic data of this study showed these to be
251 well-resolved from other neoplasms, even from the closely related FA and FTC subtypes
252 (Figure 5A; Figure S4A-S4C). Hürthle cell tumors are known for their oncocytic
253 morphology and increased glucose uptake in FDG-PET scans (Grani et al., 2018), and
254 indeed, our data showed that 91 of 109 proteins substantially elevated (fold change > 2
255 and adjusted p-value < 0.01) compared to follicular neoplasms are mitochondrial
256 proteins participating in multiple metabolic pathways including the TCA cycle and
257 oxidative phosphorylation (Figure 5B). Our data therefore uncovered biochemical
258 processes contributing to the elevated metabolism of Hürthle cell tumors. Compared to
259 the other four complexes in the oxidative phosphorylation pathway, the most strongly
260 upregulated proteins (7/16) were in complex V which catalyzes ATP synthesis and
261 potentially enhances tumor growth.

262 Follicular-variant papillary thyroid cancers (fvPTC) is a subtype with mixed

263 morphology, and we therefore examined specific differences between FTC, classical
264 papillary cancers (cPTC) and fvPTC. There were no significant proteotypic differences
265 between FTC and fvPTC (Figure S4D). However, 45 proteins were differentially
266 regulated in fvPTC compared to cPTC (Figure S4D; proteins listed in Table S5). Our
267 proteotypic data showed that fvPTC overlapped with both FTC and cPTC, but
268 resembled FTC more closely, indicating that fvPTC is potentially an intermediate entity
269 between FTC and cPTC (Figure 5C). This is consistent with genomic classifiers which
270 suggest that FTC and fvPTC share common alterations including in the RAS pathway
271 (Agrawal et al., 2014). Compared to cPTC, 50 proteins upregulated in histologically
272 distinct FTC participate in multiple biological processes including endoplasmic reticulum
273 stress and the unfolded protein response (Figure 5D, S4E), both of which are implicated
274 in bypassing Ras-driven oncogenic senescence (Blazanin et al., 2017). The signaling
275 network involving key upregulated proteins in FTC is shown in Figure S4F. In contrast,
276 the 97 proteins upregulated in cPTC compared to FTC (Figure 5E) mapped to major
277 oncogenic (TP53, MYC), dendritic cell maturation pathways and inflammatory response,
278 suggesting that canonical oncogenic pathways and inflammation are involved in the
279 pathogenesis of cPTC, which has been associated with thyroid inflammation (Figure
280 5F). Consistent with this suggestion, three proteins involved in inflammation, ANXA1,
281 LGALS3 and SOD2, showed greatest fold-change among proteins that mapped to the
282 TP53- and MYC- related networks in cPTC (Figure 5G). Intercellular adhesion molecule
283 1 (ICAM-1) and signal transducer and activator of transcription 1 (STAT1) are over-
284 expressed in cPTC and are potential immune-modulating targets.

285

286 **DISCUSSION**

287 Molecular diagnostics for thyroid nodules have been limited to nucleic acid-based
288 testing thus far due to the feasibility of analyzing small clinical samples and the
289 increasing affordability of next-generation sequencing. Several nucleic acid-based tests
290 are commercially available through central-lab testing, their performance in clinic is
291 suboptimal in terms of specificity, especially in malignancies with low mutational burden
292 as rigorously examined by Wang et al (Wang and Sosa, 2018). Since proteins are more
293 stable than RNA in biopsy tissue samples (Shao et al., 2019), we posit that our protein
294 panel can be developed as future point-of-care diagnostic tests through widely available
295 techniques such as mass spectrometry and/or immunohistochemistry, as a complement
296 to the nucleic acid-based test. The FFPE-PCT-DIA methodology used here was able to
297 derive protein abundance data of 3,779 proteins in 931 samples, generating 2,421 DIA
298 proteome data sets, including replicates. The pipeline generated the first repository of
299 proteome data of various thyroid pathologies. This enabled artificial neural network
300 analysis to mine large proteomic datasets for protein biomarkers of thyroid cancers. A
301 panel of 14 proteins differentiated benign from malignant disease with diagnostic
302 accuracy over 90% with sensitivity and specificity over 91% for retrospective test sets
303 and accuracy of 89% for prospective FNA-derived test set. The fact that 12 out of 14 of
304 these have been previously implicated in thyroid physiology or pathology provides
305 orthogonal validation for the inclusion of these proteins in our classifier. These metrics
306 from proteomics data exhibited high degree of both sensitivity and specificity as shown
307 in Table 3. Our method works for small tissue samples obtained from both FFPE tissues

308 and FNA biopsies, making it broadly applicable for standard clinical practice, bypassing
309 RNA assays due to the fragility of RNA integrity.

310 Despite the accuracy in distinguishing benign from malignant thyroid nodules, the
311 major limitation for most algorithms is distinguishing FA from FTC. Indeed, the
312 proteotype data presented here even suggests that this entity may represent a
313 continuum of disease, in which differences exist at the extremes of phenotypes, but with
314 significant overlap in-between. Alternatively, the overlapping benign categories may
315 represent precursor lesions diagnosed prior to overt capsular or vascular invasion, even
316 though pre-requisite conditions for invasion are already present in the tumors.

317 In conclusion, we present the first protein-based artificial neural networks classifier
318 for classifying thyroid nodules. Although this test has been retrospectively validated in
319 three clinical centers and prospectively validated in a fourth independent center, further
320 validation using FNA biopsy specimens from larger prospective cohorts are required.
321 This large-scale thyroid proteome profile of 931 thyroid nodules coupled with artificial
322 neural networks demonstrates the power of a protein-based disease classifier with rapid
323 potential to be translated into clinical practice. The thus established protein classifiers
324 may complement nucleic acid-based tests in multiple clinical applications. Expanding
325 this robust workflow to other carefully curated clinical cohorts may offer unprecedented
326 opportunities to gain fundamental insights into molecular pathogenesis of diseases and
327 address critical unmet clinical needs beyond thyroid cancer.

328

329 **ACKNOWLEDGEMENTS**

330 This work was supported by grants from National Natural Science Foundation of China
331 (81972492) and National Natural Science Fund for Young Scholars (21904107),
332 Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars
333 (LR19C050001), Hangzhou Agriculture and Society Advancement Program
334 (20190101A04). Further support for this project was obtained from the National Cancer
335 Centre Research Fund (Peter Fu Program) and National Medical Research Council
336 Clinician-Scientist Award (NMRC/CSAINV/011/2016), both in Singapore. The
337 prospective study was supported by National Natural Science Foundation of
338 China (81902726), China Postdoctoral Science Foundation
339 (NO. 2018M641739), Natural Science Foundation of Liaoning Province (20180530090).

340 **AUTHOR CONTRIBUTIONS**

341 T.G., N.G.I., O.L.K., S.Z.L., Y.Zhu and Y.S. designed the project. SS performed central
342 pathology review of the discovery set. H. Z. collected the samples for prospective test
343 set. L.C., X.T., Y.Zhao, G.W., J.X., Z.W., W.S., Y.Q., Y.H., L.W. and S.Z. procured and
344 annotated the Chinese thyroid tissue samples, while SS, SM, TKHL, SY, SMFSA, SSL,
345 BH procured and annotated the Singapore tissue samples. Y.S., W.L., X.C., X.Z., Q.X.,
346 H.G., X.Z. and K. X. performed the experiments. Y.S., W.L., W.W., H.C., T.Z. and Q.Z.
347 conducted proteomic data analysis. Z.Z. and S.Z.L. performed the learning analysis.
348 Y.S., N.G.I., O.L.K. and T.G. wrote the manuscript with inputs from all co-authors. T.G.,

349 N.G.I., O.L.K. and S.Z.L. supervised the project.

350 **DECLARATION OF INTERESTS**

351 The research group of T.G. is supported by Pressure Biosciences Inc, which provides
352 sample preparation instrumentation. Authors declare no competing interests.

353 **DATA AVAILABILITY**

354 All data are available in the manuscript or the supplementary material. MS raw data
355 were deposited in iProX (IPX000444000). All the data will be publicly released upon
356 publication.

357

358 **REFERENCES**

- 359 Agrawal, N., Akbani, R., Aksoy, B., Ally, A., Arachchi, H., Asa, S., Auman, J., Balasundaram, M., Balu, S., Baylin, S.,
360 *et al.* (2014). Integrated genomic characterization of papillary thyroid carcinoma. *Cell* *159*, 676-690.
- 361 Ahn, H.S., Kim, H.J., and Welch, H.G. (2014). Korea's Thyroid-Cancer "Epidemic" — Screening and
362 Overdiagnosis. *N Engl J Med* *371*, 1765-1767.
- 363 Alexander, E.K., Kennedy, G.C., Baloch, Z.W., Cibas, E.S., Chudova, D., Diggans, J., Friedman, L., Kloos, R.T., LiVolsi,
364 V.A., Mandel, S.J., *et al.* (2012). Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.
365 *N Engl J Med* *367*, 705-715.
- 366 Bartolazzi, A., Sciacchitano, S., and D'Alessandria, C. (2018). Galectin-3: The Impact on the Clinical Management
367 of Patients with Thyroid Nodules and Future Perspectives. *International journal of molecular sciences* *19*.
- 368 Becht, E., McInnes, L., Healy, J., Dutertre, C., Kwok, I., Ng, L., Ginhoux, F., and Newell, E. (2018). Dimensionality
369 reduction for visualizing single-cell data using UMAP. *Nature biotechnology*.
- 370 Blazanin, N., Son, J., Craig-Lucas, A.B., John, C.L., Breech, K.J., Podolsky, M.A., and Glick, A.B. (2017). ER stress
371 and distinct outputs of the IRE1 α RNase control proliferation and senescence in response to oncogenic Ras.
372 *Proc Natl Acad Sci USA* *114*, 9900-9905.
- 373 Brix, K., Summa, W., Lottspeich, F., and Herzog, V. (1998). Extracellularly occurring histone H1 mediates the
374 binding of thyroglobulin to the cell surface of mouse macrophages. *J Clin Invest* *102*, 283-293.
- 375 Burman, K.D., and Wartofsky, L. (2015). CLINICAL PRACTICE. Thyroid Nodules. *N Engl J Med* *373*, 2347-2356.
- 376 Ciregia, F., Giusti, L., Molinaro, A., Niccolai, F., Mazzoni, M.R., Rago, T., Tonacchera, M., Vitti, P., Giannaccini, G.,
377 and Lucacchini, A. (2016). Proteomic analysis of fine-needle aspiration in differential diagnosis of thyroid
378 nodules. *Translational research : the journal of laboratory and clinical medicine* *176*, 81-94.
- 379 Eszlinger, M., Lau, L., Ghaznavi, S., Symonds, C., Chandarana, S.P., Khalil, M., and Paschke, R. (2017). Molecular
380 profiling of thyroid nodule fine-needle aspiration cytology. *Nat Rev Endocrinol* *13*, 415-424.
- 381 Faquin, W.C., Bongiovanni, M., and Sadow, P.M. (2011). Update in thyroid fine needle aspiration. *Endocr Pathol*
382 *22*, 178-183.
- 383 Farrokhi Yekta, R., Arefi Oskouie, A., Rezaei Tavirani, M., Mohajeri-Tehrani, M.R., and Soroush, A.R. (2018).
384 Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary
385 thyroid carcinoma: A proteomic study. *Int J Biol Markers* *33*, 455-462.
- 386 Figliozzi, R.W., Chen, F., and Hsia, S.V. (2017). New insights on thyroid hormone mediated regulation of
387 herpesvirus infections. *Cell Biosci* *7*, 13.
- 388 Ganly, I., Makarov, V., Deraje, S., Dong, Y., Reznik, E., Seshan, V., Nanjangud, G., Eng, S., Bose, P., Kuo, F., *et al.*

- 389 (2018). Integrated Genomic Analysis of Hurthle Cell Cancer Reveals Oncogenic Drivers, Recurrent
390 Mitochondrial Mutations, and Unique Chromosomal Landscapes. *Cancer Cell* *34*, 256-270 e255.
- 391 Gillet, L.C., Navarro, P., Tate, S., Rost, H., Selevsek, N., Reiter, L., Bonner, R., and Aebersold, R. (2012). Targeted
392 data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent
393 and accurate proteome analysis. *Mol Cell Proteomics* *11*, O111.016717.
- 394 Gopal, R.K., Kubler, K., Calvo, S.E., Polak, P., Livitz, D., Rosebrock, D., Sadow, P.M., Campbell, B., Donovan, S.E.,
395 Amin, S., *et al.* (2018). Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers
396 in Hurthle Cell Carcinoma. *Cancer Cell* *34*, 242-255 e245.
- 397 Grani, G., Lamartina, L., Durante, C., Filetti, S., and Cooper, D.S. (2018). Follicular thyroid cancer and Hürthle cell
398 carcinoma: challenges in diagnosis, treatment, and clinical management. *The Lancet Diabetes & Endocrinology*
399 *6*, 500-514.
- 400 Guo, T., Kouvonen, P., Koh, C.C., Gillet, L.C., Wolski, W.E., Rost, H.L., Rosenberger, G., Collins, B.C., Blum, L.C.,
401 Gillessen, S., *et al.* (2015). Rapid mass spectrometric conversion of tissue biopsy samples into permanent
402 quantitative digital proteome maps. *Nat Med* *21*, 407-413.
- 403 He, Y., Cao, L., Wang, L., Liu, L., Huang, Y., and Gong, X. (2020). Metformin Inhibits Proliferation of Human
404 Thyroid Cancer TPC-1 Cells by Decreasing LRP2 to Suppress the JNK Pathway. *Onco Targets Ther* *13*, 45-50.
- 405 Jameson, J.L. (2012). Minimizing unnecessary surgery for thyroid nodules. *N Engl J Med* *367*, 765-767.
- 406 Jiang, Y., Sun, A., Zhao, Y., Ying, W., Sun, H., Yang, X., Xing, B., Sun, W., Ren, L., Hu, B., *et al.* (2019). Proteomics
407 identifies new therapeutic targets of early-stage hepatocellular carcinoma. *Nature* *567*, 257-261.
- 408 Kashat, L., So, A.K.C., Masui, O., Wang, X.S., Cao, J., Meng, X., Macmillan, C., Ailles, L.E., Siu, K.W.M., Ralhan, R.,
409 *et al.* (2010). Secretome-based identification and characterization of potential biomarkers in thyroid cancer.
410 *Journal of proteome research* *9*, 5757-5769.
- 411 Kim, H.-S., Kim, G.Y., Lim, S.-J., and Kim, Y.W. (2010). Raf-1 kinase inhibitory protein expression in thyroid
412 carcinomas. *Endocrine pathology* *21*, 253-257.
- 413 Kohavi, R. (1995). A Study of Cross-Validation and Bootstrap for Accuracy Estimation and Model Selection.
414 International Joint Conference of Artificial Intelligence.
- 415 M, G., A, W., M, P., Ł, M., M, C., K, J., D, L., R, J., A, G., and P, W. (2018). Proteome profiles of different types of
416 thyroid cancers. *Molecular and cellular endocrinology* *472*, 68-79.
- 417 Martínez-Aguilar, J., Clifton-Bligh, R., and Molloy, M.P. (2016). Proteomics of thyroid tumours provides new
418 insights into their molecular composition and changes associated with malignancy. *Sci Rep* *6*, 23660.
- 419 Mitchell, M. (1998). Elements of Generic Algorithms. An Introduction to Generic Algorithms, 158.
- 420 Nikiforova, M.N., Wald, A.I., Roy, S., Durso, M.B., and Nikiforov, Y.E. (2013). Targeted next-generation
421 sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. *The Journal of clinical endocrinology*
422 *and metabolism* *98*, E1852-1860.
- 423 Patel, K.N., Angell, T.E., Babiarz, J., Barth, N.M., Blevins, T., Duh, Q.Y., Ghossein, R.A., Harrell, R.M., Huang, J.,
424 Kennedy, G.C., *et al.* (2018). Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of
425 Cytologically Indeterminate Thyroid Nodules. *JAMA Surg* *153*, 817-824.
- 426 Rost, H.L., Rosenberger, G., Navarro, P., Gillet, L., Miladinovic, S.M., Schubert, O.T., Wolski, W., Collins, B.C.,
427 Malmstrom, J., Malmstrom, L., *et al.* (2014). OpenSWATH enables automated, targeted analysis of data-
428 independent acquisition MS data. *Nat Biotechnol* *32*, 219-223.
- 429 Schubert, O.T., Gillet, L.C., Collins, B.C., Navarro, P., Rosenberger, G., Wolski, W.E., Lam, H., Amodei, D., Mallick,
430 P., MacLean, B., *et al.* (2015). Building high-quality assay libraries for targeted analysis of SWATH MS data. *Nat*
431 *Protoc* *10*, 426-441.
- 432 Schürch, C.M., Roelli, M.A., Forster, S., Wasmer, M.-H., Brühl, F., Maire, R.S., Di Pancrazio, S., Ruepp, M.-D.,
433 Giger, R., Perren, A., *et al.* (2019). Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor
434 Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy. *Thyroid* *29*, 979-992.

- 435 Shao, S., Guo, T., Gross, V., Lazarev, A., Koh, C.C., Gillissen, S., Joerger, M., Jochum, W., and Aebersold, R. (2016).
436 Reproducible Tissue Homogenization and Protein Extraction for Quantitative Proteomics Using MicroPestle-
437 Assisted Pressure-Cycling Technology. *Journal of proteome research* *15*, 1821-1829.
- 438 Shao, S., Guo, T., Koh, C.C., Gillissen, S., Joerger, M., Jochum, W., and Aebersold, R. (2015). Minimal sample
439 requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass
440 spectrometry. *Proteomics* *15*, 3711-3721.
- 441 Shao, W., Guo, T., Toussaint, N.C., Xue, P., Wagner, U., Li, L., Charmpi, K., Zhu, Y., Wu, J., Buljan, M., *et al.* (2019).
442 Comparative analysis of mRNA and protein degradation in prostate tissues indicates high stability of proteins.
443 *Nat Commun* *10*, 2524.
- 444 Sinha, A., Huang, V., Livingstone, J., Wang, J., Fox, N.S., Kurganovs, N., Ignatchenko, V., Fritsch, K., Donmez, N.,
445 Heisler, L.E., *et al.* (2019). The Proteogenomic Landscape of Curable Prostate Cancer. *Cancer Cell* *35*, 414-427
446 e416.
- 447 Smith, A., Galli, M., Piga, I., Denti, V., Stella, M., Chinello, C., Fusco, N., Leni, D., Manzoni, M., Roversi, G., *et al.*
448 (2019). Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation
449 mass spectrometry imaging. *J Proteomics* *191*, 114-123.
- 450 Steward, D.L., Carty, S.E., Sippel, R.S., Yang, S.P., Sosa, J.A., Sipos, J.A., Figge, J.J., Mandel, S., Haugen, B.R.,
451 Burman, K.D., *et al.* (2019). Performance of a Multigene Genomic Classifier in Thyroid Nodules With
452 Indeterminate Cytology: A Prospective Blinded Multicenter Study. *JAMA Oncol* *5*, 204-212.
- 453 Sun, R., *et al.*, Guo, T. (2020). Accelerated Protein Biomarker Discovery from FFPE Tissue Samples Using Single-
454 Shot, Short Gradient Microflow SWATH MS. *Journal of Proteome Research*.
- 455 Vaccarella, S., Franceschi, S., Bray, F., Wild, C.P., Plummer, M., and Dal Maso, L. (2016). Worldwide Thyroid-
456 Cancer Epidemic? The Increasing Impact of Overdiagnosis. *N Engl J Med* *375*, 614-617.
- 457 Wang, T.S., and Sosa, J.A. (2018). Thyroid surgery for differentiated thyroid cancer - recent advances and future
458 directions. *Nat Rev Endocrinol* *14*, 670-683.
- 459 Wang, Y., He, H., Li, W., Phay, J., Shen, R., Yu, L., Hancioglu, B., and de la Chapelle, A. (2017). MYH9 binds to
460 lncRNA gene PTSC2 and regulates FOXE1 in the 9q22 thyroid cancer risk locus. *Proc Natl Acad Sci USA* *114*,
461 474-479.
- 462 Zhang, H., Liu, T., Zhang, Z., Payne, S.H., Zhang, B., McDermott, J.E., Zhou, J.Y., Petyuk, V.A., Chen, L., Ray, D.,
463 *et al.* (2016). Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. *Cell*
464 *166*, 755-765.
- 465 Zhu, T., *et al.*, Guo, T. (2020). DPHL: A pan-human protein mass spectrometry library for robust biomarker
466 discovery using Data-Independent Acquisition and Parallel Reaction Monitoring. *Genomics, Proteomic and*
467 *Bioinformatics*, <https://www.biorxiv.org/content/10.1101/2020.1102.1103.931329v931321>.
- 468 Zhu, Y., Weiss, T., Zhang, Q., Sun, R., Wang, B., Yi, X., Wu, Z., Gao, H., Cai, X., Ruan, G., *et al.* (2019). High-
469 throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. *Mol Oncol*.

470

471

472 **Table 1. Clinico-pathologic characteristics of the study cohorts.**

	Discovery dataset	Independent test datasets		All
		Retrospective test datasets	Prospective test dataset	
Total no.				
Clinical centers	1	3	1	5
patients	578	271	62	911
nodules	579	288	64	931
FFPE punches	1725	288	0	2013
Fine needle aspiration biopsies	0	0	64	64
DIA files	1781	576	64	2421
Histopathology diagnosis				
Normal thyroid tissues	40 (6.9%)	16 (5.6%)	0 (0.0%)	56 (6.0%)
Multinodular goiter	203 (35.1%)	44 (15.3%)	13 (20.3%)	260 (27.9%)
Follicular adenoma ^b	137 (23.7%)	84 (29.2%)	5 (7.8%)	226 (24.3%)
Follicular thyroid carcinoma ^b	75 (13.0%)	52 (18.1%)	0 (0.0%)	127 (13.6%)
Papillary thyroid carcinoma	124 (21.4%)	92 (31.9%)	46 (71.9%)	262 (28.1%)
Diagnosis age				
Mean	52.8	47.5	43.6	50.6
Median	54	49	44	52
Range	13-85	15-82	24-74	13-85
< 18 y	7 (1.2%)	1 (0.4%)	0 (0.0%)	8 (0.9%)
18-55 y	288 (49.8%)	173 (63.8%)	48 (77.4%)	509 (55.9%)
≥55 y	283 (49.0%)	97 (35.8%)	14 (22.6%)	394 (43.2%)
Gender				
Female	433 (74.9%)	191 (66.3%)	54 (87.1%)	678 (74.4%)
Male	145 (25.1%)	80 (27.7%)	8 (12.9%)	233 (25.6%)
Nodule size^a on ultrasonography				
Mean	3.3	2.9	2.5	3.1
Median	3.0	2.6	2.2	2.9
Range	0.2-13.0	0.2-8.9	0.6-5.5	0.2-13.0
< 1 cm	15 (2.8%)	37 (14.0%)	2 (3.1%)	54 (6.3%)
1~4 cm	342 (64.5%)	143 (54.0%)	53 (82.8%)	538 (62.6%)
≥4 cm	173 (32.6%)	85 (32.1%)	9 (14.1%)	267 (31.1%)

473 ^aNodule size information of nine patients in discovery dataset and seven patients in test dataset were not
474 record.

475 ^bHurthle cell adenoma and carcinoma were allocated into follicular thyroid adenoma and carcinoma,
476 respectively.

477

478

479
480
481

Table 2. Fourteen proteins selected by genetic algorithm, functional pathways and previously known associated thyroid physiology or pathology.

Uniprot ID	Symbol	Entrez Gene Name	Thyroid cancer related	Thyroid function related
O75347	TBCA	tubulin folding cofactor A	-	Yes
P02765	AHSG	alpha 2-HS glycoprotein	Yes	-
P04083	ANXA1	annexin A1	Yes	Yes
P04216	THY1	Thy-1 cell surface antigen	-	-
P10909	CLU	clusterin	Yes	-
P16403	HIST1H1C	histone cluster 1 H1 family member c	-	Yes
P17931	LGALS3	galectin 3	Yes	-
P26038	MSN	moesin	Yes	-
P27797	CALR	calreticulin	Yes	Yes
P30086	PEBP1	phosphatidylethanolamine binding protein 1	Yes	Yes
P35579	MYH9	myosin heavy chain 9	Yes	-
P98164	LRP2	LDL receptor related protein 2	Yes	-
Q9H299	SH3BGRL3	SH3 domain binding glutamate rich protein like 3	Yes	Yes
Q9HAT2	SIAE	sialic acid acetyltransferase	-	-

482

483
484**Table 3. Performance of the protein classifier.**

Center	Retrospective test sets			All retrospective study	Prospective test set	All
	ZY	ZE	DL		FNA	
Sample type	FFPE	FFPE	FFPE	FFPE	Biopsy	FFPE+Biopsy
Malignant nodules No.	35	61	48	144	46	190
Benign nodules No.	19	79	46	144	18	162
Prevalence ^a	64.81 (53.62 - 74.59)	43.57 (36.84 - 50.54)	51.06 (42.65 - 59.42)	50.00 (45.16 - 54.84)	71.88 (61.86 - 80.11)	53.98 (49.58 - 58.31)
Predict M/M ^b	31	58	41	130	40	170
Predict B/B ^c	17	71	43	131	16	147
Sensitivity	88.57 (76.80 - 94.78)	95.08 (88.29 - 98.02)	85.42 (75.12 - 91.91)	90.28 (85.43 - 93.63)	86.96 (76.67 - 93.12)	89.47 (85.23 - 92.61)
Specificity	89.47 (72.59 - 96.46)	89.87 (82.88 - 94.21)	93.48 (84.73 - 97.37)	90.97 (86.23 - 94.19)	88.89 (71.30 - 96.26)	90.74 (86.28 - 93.85)
PPV	93.94 (86.86 - 97.76)	87.88 (82.57 - 91.70)	93.18 (88.11 - 96.67)	90.91 (87.79 - 93.39)	95.24 (88.81 - 98.12)	91.89 (89.01 - 93.87)
NPV	80.95 (71.33 - 88.61)	95.95 (91.91 - 97.77)	86.00 (79.27 - 91.03)	90.34 (87.01 - 92.79)	72.73 (63.51 - 81.45)	88.02 (84.92 - 90.63)
Accuracy	88.89 (79.89 - 94.16)	92.14 (87.54 - 95.14)	89.36 (82.96 - 93.54)	90.62 (87.40 - 93.09)	87.50 (79.12 - 92.82)	90.06 (87.11 - 92.39)
Youden's index	0.78	0.85	0.74	0.81	0.76	0.80

485
486
487
488
489

Each value was calculated to 95% Wilson confidence intervals.

^aThe ratio of carcinoma in total nodules.^bThe number of benign nodules identified as benign.^cThe number of malignant nodules identified as malignant.

490 **FIGURE LEGEND**

491 **Figure 1. Schematic view of the study and batch design.** (A) The project design and
492 workflow of the FFPE PCT-DIA pipeline. (B-C) Batch design (B) The discovery group of
493 579 thyroid nodules from 578 patients consisted of 40 normal thyroid, 203 multinodular
494 goiter, 137 follicular thyroid adenoma, 75 follicular thyroid carcinoma and 124 papillary
495 thyroid carcinomas with unblinded diagnoses. Each nodule was represented by three
496 cores as biological replicates. 1,781 thyroid FFPE punches and 56 technical replicates
497 were randomly allocated into 121 discovery batches in order to minimize batch effect for
498 this large-scale sample preparation. (C) The independent test group contained two
499 parts, one is retrospective test group and the other is prospective test group.
500 Retrospective test group included 288 thyroid nodules of blinded diagnoses from 271
501 patients. Each nodule was analyzed in technical duplicates, without biological replicates.
502 A total of 288 FFPE cores and 288 corresponding technical duplicates were divided into
503 44 batches for analysis. Prospective test group contained 64 fine needle aspiration
504 biopsies of thyroid nodules from 64 patients which were divided into 5 batches. Each
505 batch consisted of 15 thyroid samples, one mouse liver sample and one pooled thyroid
506 sample.

507
508 **Figure 2. Global thyroid proteome profile.** (A) Heatmap showing global protein
509 expression profiles of the five main histological types of thyroid tissues. 579 thyroid
510 tissues from 578 patients are in columns and 2,617 proteins (missing value <90%) in
511 rows. The color bar indicates the intensity of the proteins. (B-F) UMAP plots showing
512 global snapshots comparing the indicated types thyroid tissues using 2,617 proteins for
513 (B) all subtypes; (C) benign versus malignant; (D) only benign; (E) FA versus FTC; and
514 (F) only malignant tissue types.

515
516 **Figure 3. Classifier development, performance testing and validation in**
517 **independent blinded datasets.** (A) Schematic of principal classifier model (details in
518 Supplementary Methods). (B) ROC plots of seven different machine learning model
519 under 14 selected features. (C) t-SNE plot showing the separation between benign
520 malignant groups in the discovery set using 14 protein features with latent space; and
521 ROC plots of the training and validation sample subgroups of the discovery set. (D-E) t-
522 SNE and ROC plots of the performance for (D) retrospective test sets; and (E)
523 prospective test set (total cohort and individual hospital sites as indicated). (F) Overall
524 performance metrics of prediction of the neural network model for five specific
525 histopathological types per site. Graduated colors in the shaded bar indicate accuracy
526 levels. Numbers in the boxes indicate the number of correctly identified samples/total
527 sample number.

528
529 **Figure 4. Protein expression plots for 14 selected protein features in the five**
530 **types of thyroid tissues in the discovery cohort.** Y-axis shows Log₂ values of
531 protein expression intensity and x axis indicates tissue type. P-value was calculated by
532 one-way ANOVA. Further protein details are listed alongside each plot.

533

534 **Figure 5. Biological insights of thyroid tumor subtypes based on proteotypic data.**

535 (A) UMAP plot for 109 proteins distinguishing Hürthle cell from other follicular
536 neoplasms. (B) Network map showing expression of key mitochondrial proteins
537 implicated in Hürthle cell neoplasms. (C) UMAP plot for 175 proteins distinguishing FTC
538 from cPTC, with fvPTC as an intermediate phenotype. (D) Heatmap showing
539 differentially expressed proteins in FTC compared with fvPTC and cPTC, with pathways
540 as indicated. X-axis of the vertical bar plot indicates $-\log_2(\text{p-value})$ based on right-tailed
541 Fisher's exact test from the IPA database. (E) Volcano plot showing 50 up-regulated
542 proteins in FTC and 97 up-regulated proteins in cPTC with two-fold-change cutoff and
543 adjusted p-value threshold less than 0.01. (F) Proteins in the cPTC network participate
544 in immune pathways and oncogenesis (MYC and TP53 pathways). (G) Box plots
545 showing three proteins specifically overexpressed in cPTC compared to other
546 histological subtypes.

547

548 **MATERIALS AND METHODS**

549 **Patients and tissue samples**

550 Tissue cores (1 mm diameter, approximate weight 0.6 mg, including was) were
551 punched from blocks of formalin-fixed paraffin embedded (FFPE) thyroid tissues
552 obtained from four clinical centers in Singapore and China spanning 2011-2019, with
553 ethics approval of each hospital.

554 The discovery sample set of 579 thyroid nodules from 578 patients comprised
555 follicular adenomas (FA, 137 cases), multinodular goiters (MNG, 203 cases), papillary
556 thyroid carcinoma (PTC, 124 cases) and follicular thyroid carcinoma (FTC, 75 cases)
557 from the Singapore General Hospital. Hematoxylin and eosin-stained slides from tissue
558 blocks of each patient were reviewed by an experienced histopathologist who marked
559 out the disease region for tissue coring. Normal thyroid tissues (N, 40 cases) were taken
560 from cases of laryngectomy or pharyngo-laryngo-esophagectomy in which the thyroid
561 gland was surgically removed incidental to radical surgery. These patients had no
562 history of thyroid disease, prior chemotherapy or radiation. Three tissue cores were
563 made for each case as biological replicates.

564 For multi-center blinded test sets, we firstly analyzed a total of 288 FFPE tissue
565 cores from 271 cases composed of 44 MNG, 84 FA, 52 FTC and 92 PTC cases in
566 retrospective test sets. Sixteen cores were of adjacent normal thyroid tissue (N). A
567 single punch was made from each case. Furthermore, we tested 64 fine needle
568 aspiration biopsies containing 13 MNG, 5 FA and 46 PTC cases in prospective test set.
569 Histological diagnoses of these cores were blinded during the entire validation workflow
570 of sample processing, mass spectrometry analysis and predictive data analysis.

571 Cases of microcarcinoma, extensive thyroiditis and/or inflammation were excluded
572 from the discovery sample set.

573

574 **Batch design**

575 To minimize batch effects among different lots of analyzed samples, 1,725 FFPE
576 cores from 579 thyroid nodules and 56 peptides extracted from cores selected as
577 technical replicates from the discovery sample set were randomly distributed into 121
578 batches. Each batch contained 15 thyroid samples, one mouse liver sample as quality
579 control (QC) for PCT and one thyroid pooled sample containing all five types of thyroid
580 tissues for mass spectrometry (MS). In this discovery phase analysis, the histopathology
581 diagnosis of each tissue core was known from which models of data segregation were
582 established.

583 In the test phase analysis, 288 FFPE cores were analyzed in technical duplicates
584 for a total of 576 samples in 44 batches for retrospective test sets and 64 fine needle
585 biopsies in 5 batches for prospective test set (Figure S1).

586

587 **Dewaxing, rehydration and hydrolysis of FFPE tissues**

588 For each case in the discovery sample set, three biological replicates of FFPE
589 tissue cores were processed. Sample weights were recorded before dewaxing in
590 heptane (Sigma) and successively in 100% ethanol (Sigma), 90% ethanol, 75% ethanol
591 at room temperature. Formic acid (0.1%) (Sigma) was added next for achieve C-O
592 hydrolysis of protein methylol products and then washed with 100 mM Tris-HCl (pH10,
593 Sigma) to establish conditions for base hydrolysis at 95°C. The sample was then snap
594 cooled to 4°C.
595

596 **Tissue lysis, protein extraction and protein digestion**

597 Dewaxed samples were lysed in 6M urea (Sigma) and 2M thiourea (Sigma) using
598 pressure cycling technology (PCT) programmed for 90 cycles of 25 s at 45,000 p.s.i.
599 and 10 s at ambient pressure at 30°C. After lysis, 10 mM Tris(2-carboxyethyl) phosphine
600 hydrochloride and 40 mM iodoacetamide were simultaneously added to the solution and
601 incubated in the dark with gentle vortexing for 30 min, after which lysC (Hualishi
602 Scientific) was added at a ratio of 40:1 (protein to lysC). PCT-assisted lysC digestion
603 was performed with the following setting: 45 cycles of 50 s at 20,000 p.s.i. and 10 s at
604 ambient pressure at 30°C. Final tryptic digestion was performed at a ratio of 40:1
605 (protein to trypsin) by PCT with the following setting: 90 cycles of 50 s at 20,000 p.s.i.
606 and 10 s at ambient pressure at 30°C. Peptides were desalted before LC-MS analysis.
607

608 **DIA library construction**

609 DIA (data-independent acquisition) library was built as described previously (Guo et
610 al., 2015; Schubert et al., 2015). To build the spectral library for analyzing DIA files from
611 thyroid tissue samples, we collected tissue samples from the all five types of patient
612 groups into a single pool. The tissue samples were either fractionated into six fractions
613 using strong cation exchange (SCX) or processed with PCT-assisted lysis and in-
614 solution digestion, or PCT-assisted lysis and PCT-assisted digestion. Finally, peptides
615 were desalted on C18 columns.

616 Desalted peptides were separated by Ultimate 3000 nanoLC-MS/MS system
617 (Dionex LC-Packing, Amsterdam, The Netherlands) equipped with 15 cm* 75 µm ID
618 fused silica column custom packed with 1.9 µm 100 Å C18 AQUA. Peptides were
619 separated on a 120 min (148 min inject-to-inject) LC gradient at 300 nL/min in a 3-25%
620 linear gradient (buffer A: 2% acetonitrile, 0.1% formic acid; buffer B: 98% acetonitrile,
621 0.1% formic acid). Eluted peptides were ionized at a potential of +2.0 kV into Q Exactive
622 HF mass spectrometer (Thermo Fisher, Bremen, Germany). The full MS was measured
623 at resolution 60,000 (at m/z 200) in an Orbitrap using an AGC target value of 3E6
624 charges. The top 20 peptide signals (charge-states +2 and higher) were submitted to
625 fragmentation in HCD cell (higher-energy collision, 27% normalized collision energy),
626 and then transferred to Orbitrap for MS/MS analysis. MS/MS spectra were acquired at
627 resolution 30,000 (at m/z 200) in Orbitrap using an AGC target value of 1E5 charges, a
628 maxIT of 80 ms and the dynamic exclusion time was 30 s.

629 In total, we acquired 52 DDA files including 20 SCX fraction files, 18 in-solution

630 digestion files and 14 PCT-assisted digestion files on a QE-HF mass spectrometer in
631 DDA mode (Table S2). All DDA files were centroided and converted to mzXML using
632 msConvert from ProteoWizard with parameters ‘—mzXML --filter “peakPicking true
633 [1,2]”’. We analyzed DDA files using pFind version 3.1.3 with SwissProt fasta files
634 (20,269 protein sequences), and identified 47,229 transition groups, 33,802 peptides,
635 5,190 protein groups and 4,048 proteotypic proteins.
636

637 **DIA-MS data analysis**

638 Peptides were separated by using Ultimate 3000 or nanoLC-MS/MS system
639 (DIONEX UltiMate 3000 RSLCnano System, Thermo Fisher Scientific™, San Jose,
640 USA) equipped with 15cm*75 μ m ID fused silica column custom packed with 1.9 μ m
641 120 Å C18 aqua. Peptides were separated on a 45 min (68 min inject-to-inject) LC
642 gradient at 300 nL/min in a 3-25% linear gradient (buffer A: 2% acetonitrile, 0.1% formic
643 acid; buffer B: 98% acetonitrile, 0.1% formic acid). Peptides eluted from analytical
644 columns were ionized at a potential +2.0 kV into Q Exactive HF mass spectrometer (Q
645 Exactive Hybrid Quadrupole-Orbitrap, Thermo Fisher Scientific™, San Jose, USA). A
646 full MS scan was acquired analyzing 390-1010 m/z at resolution 60,000 (at m/z 200) in
647 the Orbitrap using an AGC target value of 3E6 charges and maximum injection time of
648 100 ms. After the full MS scan, 24 MS/MS scans were acquired, each with a 30,000
649 resolution (at m/z 200), AGC target value of 1E6 charges, normalized collision energy of
650 27%, with the default charge state set to 2, maximum injection time set to auto. The
651 cycle of 24 MS/MS scans (center of isolation window) with three kinds of wide isolation
652 window was as follows (m/z): 410, 430, 450, 470, 490, 510, 530, 550, 570, 590, 610,
653 630, 650, 670, 690, 710, 730, 770, 790, 820, 860, 910, 970. The entire cycle of MS and
654 MS/MS scan acquisition took approximately 3 seconds and was repeated throughout
655 the LC/MS analysis. DIA raw files were analyzed using OpenSWATH v2.0 (Rost et al.,
656 2014).
657

658 **Data quality control**

659 We first assessed data quality by analyzing samples. The QC samples were mouse
660 liver samples (PCT-QC) and pooled thyroid samples (DIA-QC) in each batch. Additional
661 QC samples were analyzed as technical replicates for MS. Biological replicates were
662 also analyzed to determine the extent of heterogeneity of thyroid diseases.
663 Reproducibility of spiked-in mouse liver samples and thyroid pooled samples showed
664 that PCT and MS instruments were stable during data acquisition (Figure S2A and B),
665 with median coefficient of variance (CV) less than 0.03. MS data of 56 randomly
666 selected paired thyroid samples in the discovery cohort had a median Spearman
667 correlation coefficient of 0.9 (Figure S2C). CV for proteins in biological replicates was
668 0.2, indicating minimal tissue heterogeneity in the biology of thyroid disease (Figure
669 S2D). Spearman correlations of four pooled samples and mouse liver samples are
670 higher than 0.9 in prospective test set (Figure S2E and F)
671

672 **Development of neural network classifier**

673 A neural network classifier is developed to classify any given proteome data sample
674 (of 14 features) into one of two classes, benign (B) or malignant (M), so as to achieve
675 the best accuracy. This comprises 4 stages:

- 676 (1) Protein data preprocessing;
- 677 (2) Protein feature selection using a genetic algorithm (GA);
- 678 (3) Learning a neural network (DNN)-based classifier;
- 679 (4) Using the trained DNN for sample classification.

680 The following details the algorithms for the 4 stages.

681 Stage 1: Data preprocessing

682 Four datasets from 5 cohorts, denoted SG, ZY, ZE, DL, FNA, were used for the
683 development of the DNN model. There, 500 random samples from the SG cohort were
684 used to train the model, 79 from the same cohort were used for internal validation, and
685 data from the ZY, ZE, DL and FNA cohorts were used for external validation. Note that
686 the external validation datasets are different those of training and internal validation. A
687 data sample in these datasets consists of 3,708 proteins.

688 The preprocessing consists of two steps: (1) missing value imputation and (2)
689 normalization. Missing values are inevitably a feature of protein intensity data.
690 Considering most missing values occur when the protein content is below a detection
691 threshold, the imputation is done by filling in all the missing values with $0.8 * D_{min}$, where
692 D_{min} is the minimum of all feature values in the training and validation sets and for this
693 work, $D_{min} = 13$.

694 Thereafter, for each feature D after the imputation step, the mean μ and variance
695 σ of that feature are estimated from the training and validation sets, and the feature of
696 every training sample is normalized according to the following

$$697 \quad D^n = \frac{D - \mu}{\sigma} \quad (a)$$

698 where D^n is the normalized feature. The obtained μ and σ are applied to the
699 corresponding protein features in the testing phase afterwards.

700 Python's pandas library is used to complete data preprocessing.

701 Stage 2: Features selection

702 Feature selection is needed for two reasons: (1) most of the 3,708 proteins are
703 useless or may be conflicting for the classification and they should be removed from
704 consideration in DNN-based classifier learning; (2) it is desired to minimize the number
705 of proteins in clinical applications. It is done in two steps (Figure S5A).

706 The first step is feature screening. Out of the initial 3,708 protein features, 521 were
707 selected from differentially expressed protein of benign and malignant samples in the
708 SG dataset and from published literatures related to thyroid or thyroid cancer. Among
709 the 521, 64 did not appear in our datasets and are excluded, with 477 candidates
710 remaining. Further, if such a protein has a deletion rate greater than 45%, then it is
711 removed, with 275 proteins left. Even further, a pair of protein are removed if the
712 absolute value of the Pearson correlation between them is less than 0.1, yielding the
713 243 candidate proteins.

714 As the second step, a combinatorial optimization is performed to select a best
715 combination of 14 proteins from the 243. While no algorithms can guarantee a globally
716 optimal solution with efficiency, here a genetic algorithm (GA)(Mitchell, 1998) was used
717 to find the best 14 proteins.

718 In GA, evolutionary operation (crossover, mutation, and selection operations) are
719 used to generate new protein feature combinations from existing protein features
720 combinations. At every iteration, the GA eliminates the low fitness combinations, and
721 generates new combinations based on the remaining high fitness combinations.

722 A fitness value is calculated for each candidate combination solution (gene chain).
723 For gene chain C , it is defined as

$$724 \quad F^C = \frac{1}{5} \sum_{k=1}^5 A_k^C \quad (b)$$

725 where A_k^C is the accuracy of the k -th cross-validation(Kohavi, 1995), which is
726 computed from the difference between the output of the classifier and the true label.

727 Python's deap library is used to complete features selection.

728 Stage 3: Model training

729 The DNN classifier is a nonlinear function which takes a vector of 14 selected
730 protein features as the input and produces a class label of either 1 (for malignant) or 0
731 (for benign) as the output. This consists of the following 3 steps: (1) model structure
732 design; (2) loss function design; and (3) model training.

733 A multi-layer perceptron (MLP) structure is chosen for the DNN, shown in Figure
734 S5B, The MLP model is divided into feature extraction sub-model and classification sub-
735 model, trained in sequence as will be described below. The feature extraction sub-
736 model extracts effective feature vectors (V_p), and the classification sub-model completes
737 classification diagnosis based on the classification information.

738 Once the DNN structure is defined, the parameterized nonlinear function is trained
739 to achieve the best objective value as measured by a loss function. The loss function of
740 the MLP is defined as

$$741 \quad L = \alpha_1 L_c + \alpha_2 L_e + \alpha_3 L_r \quad (c)$$

742 where L_c is a contrastive loss (Becht et al., 2018) for training the feature extraction
743 sub-model, L_e is a cross-entropy loss for training the classification sub-model, L_r is an
744 L2 regularization loss for reducing overfitting, and $\alpha_1, \alpha_2, \alpha_3 > 0$ are the weights.

745 The contrastive loss L_c is defined under the Siamese Network (SN) structure. The
746 contrastive loss L_c is calculated as

$$747 \quad L_c(p, q) = \begin{cases} \|V_p - V_q\|^2 & \text{if } p, q \text{ in the same class} \\ \max(M - \|V_p - V_q\|^2, 0)^2 & \text{others} \end{cases} \quad (d)$$

748 where feature vectors V_p, V_q extracted from protein samples X_p and X_q , $\|V_p - V_q\|$ is
749 the distance, and M is the margin ($M=1$ in this work),. The contrastive loss encourages
750 reduction of within-class feature scatter and increase of between-class feature scatter.

751 The cross-entropy loss L_e is calculated as

752
$$L_e = -[\beta_1 Y \log \hat{Y} + \beta_2 (1 - Y) \log (1 - \hat{Y})] \quad (e)$$

753 where Y is the real label of the patient, \hat{Y} is the classification score predicted by
754 classification sub-model, and β_1, β_2 are penalty parameters ($\beta_1 = 0.725, \beta_2 = 1.275$ in
755 this work). The L2 regularizer is defined as the 2-norm of MLP weight W as follows

756
$$L_r = \|W\|_2^2 = \sum_{i=1}^N w_i^2 \quad (f)$$

757 where N is the number of the layer.

758 The MLP training is done with the help of the training dataset (SG), in which the
759 class label is provided for each sample as the supervisor to guide the training process.
760 The MLP training process consists of two parts. The first part trains the feature
761 extraction sub-model for 100 epochs, with $\alpha_1 = 1, \alpha_2 = 0, \alpha_3 = 0.04$ and learning rate
762 1×10^{-5} . The second part uses the cross-entropy loss training the classification sub-
763 model for 900 epochs, with $\alpha_1 = 0, \alpha_2 = 1, \alpha_3 = 0.029$ and learning rate 5×10^{-4} ,
764 while the feature extraction sub-model parameters are not frozen for faster
765 convergence. The obtained accuracy for the training set is 93%, and that for the
766 validation set is 91%.

767 Python's pytorch library is used to complete model training.

768 Stage 4: Classification

769 The trained MLP is used as the classifier for diagnosis of unknown samples.
770 Given the 14 features, the MLP outputs a classification score \hat{Y} between 0 and 1
771 and the class prediction P is calculated as follows

772
$$P = \begin{cases} 1 & \text{if } \hat{Y} > 0.5 \\ 0 & \text{if } \hat{Y} < 0.5 \end{cases} \quad (g)$$

773 where $P=0$ means the tissue is predicted to be benign, and $P=1$ malignant.

774

775 **Statistical analysis**

776 Statistical analysis was performed using R software (version 3.5.1) with pheatmap,
777 UMAP and R package plot functions. CV was calculated as the ratio of the standard
778 deviation to the mean. The prevalence for each cohort was based on the ratio of
779 malignant to total tissues. Sensitivity, specificity, PPV and NPV values were calculated
780 following the established methodology and each value was calculated with 95% Wilson
781 confidence intervals (Steward et al., 2019). Biological insights were analyzed by
782 Ingenuity Pathway Analysis (IPA version 49309495). P values were calculated by one-
783 way ANOVA in the expression of 14 protein features.

784 **Figure S1. Data quality evaluation.** (A) CV of identified protein numbers for 116 and
785 36 pooled thyroid samples in the discovery set and retrospective test sets, respectively.
786 (B) CV of identified protein numbers for 112 and 18 mouse liver samples in discovery
787 and retrospective test sets, respectively. (C) Spearman correlation of paired technical
788 replicates from 56 randomly selected thyroid samples in the discovery group and 288 in
789 the retrospective test sets. (D) CV for the number of proteins in biological replicates of
790 the discovery set. (E) Spearman correlation of four pooled samples in prospective test
791 set. (F) Spearman correlation of four mouse liver samples in prospective test set.

792
793 **Figure S2. Uniform manifold approximation and projection (UMAP) analysis of**
794 **five subtypes of thyroid tissues.** 2,617 proteins for which missing value was less than
795 90% were used in data analysis. (A) All tissue types, showing FA distributed across
796 benign (N and MNG) and malignant (FTC and PTC) tissues, (B) FA, (C) FTC, (D) PTC
797 vs N, respectively, and (E) FA, (F) FTC and (G) PTC vs MNG, respectively. Normal
798 tissue is generally well separated from all other lesional tissue, while MNG shows some
799 overlap with FA, FTC and PTC.




800
801 **Figure S3. Cross-validation of the classifier on discovery set and performance on**
802 **test sets.** (A) Scatter diagram showing the predicted malignancy scores for discovery
803 (training and validation), and tests sets (retrospective and prospective test sets), and the
804 probability for each sample to be malignant. X axis indicates the probability of
805 malignancy. Y axis represents the number of thyroid tissues in different sets. (B) t-SNE
806 plots showing specific tissue types (benign and malignant) based on the 14 protein
807 features in the training set, validation set, retrospective and prospective test sets,
808 labeled by each of the 5 subtypes. (C) t-SNE plots based on the 14 proteins for each of
809 the four clinical sites for the different test sets.

810
811 **Figure S4. Biological insights into Hürthle cell tumors, follicular (FTC), classical**
812 **papillary (cPTC) and follicular-variant PTC (fvPTC).** (A) Heatmap showing proteotype
813 expression of thyroid tissue samples highlighting differentially expressed proteins in the
814 Hürthle cell neoplasm marked in red frames. The subtype label of heatmap were based
815 on reviewed slides by experienced pathologist. (B) Graph showing cellular component
816 analysis of the 109 over-expressed proteins in Hürthle cell neoplasms. Mitochondrial
817 proteins are the most dominant group. (C) Graph showing enriched pathways based on
818 109 over-expressed proteins of Hürthle cell tumors by IPA analysis. Y-axis shows -
819 $\log_2(p\text{-value})$ based on right-tailed Fisher's exact test (IPA) based on the IPA database.
820 (D) Volcano plots showing differentially expressed proteins between fvPTC vs FTC and
821 cPTC vs fvPTC. Protein intensities used were from the average intensity of three
822 biological replicates. We compared pair-wise groups, and highlighted proteins that were
823 significantly different with two-fold-change cutoff and adjusted p-value threshold less
824 than 0.01. (E) Pathway enrichment of 50 upregulated proteins in FTC compared with
825 cPTC as analyzed by IPA. Y axis indicates $-\log_2(p\text{-value})$ based on right-tailed Fisher's
826 exact test based on the IPA database. (F) Network map showing overexpressed
827 proteins in FTC.

828
829 **Figure S5. Structures of models.** (A) Flow diagram of genetic algorithm for protein
830 features selection, i is the index of iteration, g is the index of gene chains. N_g is the
831 population size (number of the gene chains), N_i is the maximum number of iterations.
832 $C_{i,g}^b$ is the binary codes of i -th iteration g -th gene chain. $F^{C_{i,g}^b}$ is the fitness function of
833 $C_{i,g}^b$. (B) DNN's structure diagram with optimal parameters. p is the index of the
834 patients, X_p is the protein feature inputting to the feature extraction sub-model, V_p is
835 the output of the extraction sub-model, \hat{Y}_p is the output of the classification sub-model
836 and the classification score predict by DNN, N is the number of neurons in the layer.

837

Figure 1. Schematic view of the study and batch design.




N Normal thyroid
M Multinodular goiter
A Follicular adenoma
C Follicular thyroid carcinoma
P Papillary thyroid carcinoma
? Unknown thyroid tissues
Y Control for PCT (mouse liver)
Z Control for DIA (Thyroid tissue pooled sample)

838

839

840

Figure 2. Global thyroid proteome profile.




841


842

843 **Figure 3. Classifier development, performance testing and validation in**
 844 **independent blinded datasets.**



A




B




C



D



E



F


	N	MNG	FA	FTC	PTC	All
ZY	NA	NA	17/19	12/15	19/20	48/54
DL	15/16	NA	28/30	21/25	20/23	84/94
ZE	NA	40/44	31/35	10/12	48/49	129/140
FNA	NA	11/13	5/5	NA	40/46	56/64
All	15/16	51/57	81/89	43/52	127/138	317/352

80%
 85%
 90%
 95%
 100%

845

846


847 **Figure 4. Classifier development, performance testing and validation in**
848 **independent blinded datasets.**



849
850

851


Figure 5. Biological insights of thyroid tumor subtypes based on proteotypic data.



852

853


Figure S1. Data quality evaluation.



857

858

Figure S2. Uniform manifold approximation and projection (UMAP) analysis of five subtypes of thyroid tissues.




859

860

861

Figure S3. Cross-validation of the classifier on discovery set and performance on test sets.


862



863

864

865 **Figure S4. Biological insights into Hürthle cell tumors, follicular (FTC), classical**
 866 **papillary (cPTC) and follicular-variant PTC (fvPTC).**




867

868


869

Figure S5. Structures of artificial neural network models.

A



B



(b) DNN's structure diagram with optimal parameters

870

871